Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

British Journal of Ophthalmology

Volumn 94, Issue 3, 2010, Pages 284-288

  Yamada, Yukiko ^a   Sugita, Sunao ^a   Tanaka, Hiroyuki ^a   Kamoi, Koju ^a   Kawaguchi, Tatsushi ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; ISONIAZID; PREDNISOLONE;

ADULT; ARTICLE; ATOPIC DERMATITIS; BEHCET DISEASE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; NEPHROTOXICITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SKIN PRURITUS; SYSTEMIC THERAPY; TREATMENT DURATION; UVEITIS; UVEORETINITIS; VISUAL ACUITY;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; CYCLOSPORINE; DRUG EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL ACUITY;

EID: 77949497552     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.158840     Document Type: Article

References (17)

1. Nakamura S, Sugita M, Tanaka T, et al. In vitro tumor necrosis factor-alpha producibility in peripheral monocytes in patients with Behçet's disease. Nippon Ganka Gakkai Zasshi 1992;96:1282- 5.
2. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128-32.
3. Sartani G. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci 1996;37:2211-18.
4. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse - human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
5. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
6. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354:1932-9.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-9.
8. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6.
9. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001;358:1644.
10. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8.
11. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades - Behçet disease. Ann Intern Med 2004;140:404-6.
12. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Begcet's disease. An open label trial. Arthritis Rheum 2005;52:2478-84.
13. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007;51:191-6.
14. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 2007;46:1161-4.
15. Behçet's Disease Research Committee of Japan. Behçet's disease: guide to diagnosis of Behçet's disease. Jpn J Ophthalmol 1974;18:291-4.
16. Mizushima Y. Recent research into Behçet's disease in Japan. Int J Tissue React 1988;10:59-65.
17. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a- neutralizing agent. N Engl J Med 2001;345:1098-104.